Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2E)-2-[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)methylidene][1,3]thiazolo[3,2-a]benzimidazol-3(2H)-one
inhibition of GEF-Rac1 interaction (selective for Trio)
2-(morpholin-4-ylmethyl)-5-[(5-[[7-(trifluoromethyl)quinolin-4-yl]sulfanyl]pentyl)oxy]-4H-pyran-4-one
inhibition of Rac1 nucleotide binding possiblly using an allosteric mechanism
2-amino-8-hydroxy-9-[3-hydroxy-2-(hydroxymethyl)cyclopentyl]-5,9-dihydro-6H-purin-6-one
inhibition of Rac1-dependent NADPH oxidase activity
3-(2-hydroxyphenyl)-N-[4-(piperidin-1-ylsulfonyl)phenyl]-1H-pyrazole-5-carboxamide
inhibition of GEF-Rac1 interaction (Tiam1, Trio, and Vav2), the compound inhibits lamellipodia formation and smooth muscle cell migration
3-([(2E)-2-cyano-3-(4-methoxy-3-[(naphthalen-1-ylcarbonyl)oxy]phenyl)prop-2-enoyl]amino)benzoic acid
5'-p-fluorosulfonylbenzoylguanosine
-
irreversible substrate analogue-binding
5-(3-chloro-4-[(3-fluorobenzyl)oxy]-5-methoxybenzyl)-1-(4-hydroxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
5-chloro-3-(2-oxo-2-(4-[3-(trifluoromethyl)phenyl]piperazin-1-yl)ethyl)-1H-indole-2-carboxylic acid
9-methoxy-5-(3-nitrophenyl)-2-phenyl-3,10b-dihydropyrazolo[1,5-c][1,3]benzoxazine
inhibition of effector-Rac1 interaction (p67phox)
atorvastatin
-
marketed as Lipitor, i.e. [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, inhibits RhoA activity by reducing Rho geranylgeranylation
Calmodulin
-
binding of calmodulin to GST-immobilized Kir/Gem peptide inhibits GTP binding
cerivastatin
-
marketed as Baycol/Lipobay, i.e. (E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-dipropan-2-yl-pyridin-3-yl]-3,5-dihydroxy-hept-6-enoic acid, RhoA inhibitor
Clostridium botulinum exoenzyme C3
-
EDTA
inhibits nucleotide binding to Ras; inhibits nucleotide binding to Ras; inhibits nucleotide binding to Ras
ethyl ([2-(2-methoxy-4-((Z)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl)phenoxy)ethyl]sulfanyl)acetate
ethylenediaminetetraacetic acid
-
binding of GTP completely abolished
GTPase activating protein
-
-
-
GTPgammaS
-
Arl6 is competitively inhibited by the increasing concentrations of non-radioactive GTPgammaS
guanine nucleotide dissociation inhibitor GDI
-
lovastatin
-
marketed as Mevacor, i.e. 8-[2-(4-hydroxy-6-oxo-oxan-2-yl)ethyl]-3,7-dimethyl-1,2,3,7,8,8a-[hexahydronaphthalen-1-yl]2-methylbutanoate
N-(2-acetylphenyl)-4-([2-(4-chloro-2-methylphenoxy)propanoyl]amino)benzamide
N-(2-chlorobenzyl)-N-[[(4-methylphenyl)sulfonyl]carbamoyl]-L-alanine
-
Rho toxin from Clostridium botulinum, ADP-ribosylates and specifically inactivates rho-1
N-[4-methoxy-3-(piperidin-1-ylsulfonyl)phenyl]-1H-indazole-3-carboxamide
inhibition of GEF-Rac1 interaction (Tiam1)
N4-(9-ethyl-9H-carbazol-3-yl)-N2-[3-(morpholin-4-yl)propyl]pyrimidine-2,4-diamine
inhibition of GEF-Rac1 interaction (selective for Vav2)
N6-(2-[[5-(diethylamino)pentan-2-yl]amino]-6-methylpyrimidin-4-yl)-2-methylquinoline-4,6-diamine
a selective inhibitor for Rac1. The small molecule fits into the surface groove of Rac1 involved in the binding with GEFs, thus interfering with the Tiam1-Rac1 interaction
p21 activated kinase
PAK, inhibits nucleotide dissociation from enzyme; PAK, inhibits nucleotide dissociation from enzyme
-
PlexA
plexins (Plexs) comprise a large family of cell surface receptors for semaphorins (Semas) that function as evolutionarily conserved guidance molecules. Rap GTPase but not Ras GTPase homologs are inactivated by the GAP activity of several vertebrate plexins. GTPase activating protein (GAP) activity for Ras family small GTPases has been implicated in plexin signaling cascades through its RasGAP domain. Neuronal expression of mutant PlexA robustly restores defasciculation defects in PlexA null mutants when the catalytic arginine fingers of the PlexA RasGAP domain critical for GAP activity are disrupted. Deleting the RasGAP domain abolishes the ability of PlexA to rescue the PlexA guidance phenotypes. PlexA-mediated motor axon guidance is dependent on the presence of the PlexA RasGAP domain, but not on its GAP activity toward Ras family small GTPases
-
Rap1Gap
-
the GTPase activating protein catalyzes the hydrolysis of GTP by its asparagine side chain rendering Rap1 inactive
-
simvastatin
-
marketed as Zocor, i.e. [(1S,3R,7R,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-oxan-2-yl]ethyl]3.7-dimethyl]-1,2,3,7,8,8a-[hexahydronaphthalen-1-yl]2,2-dimethylbutanoate
statin
improves redox state in saphenous vein grafts in patients undergoing to coronary artery bypass grafting by inhibiting Rac1-mediated activation of NADPH oxidase
Yersinia outer protein T
-
Yersinia outer protein T is a cysteine protease that cleaves Rho protein directly upstream of the post-translationally modified cysteine, thereby releasing the GTPase from the membrane leading to inactivation, farnesylated RhoA is a preferred substrate of Yersinia outer protein T compared with the geranylgeranylated GTPase, geranylgeranylated RhoA, however, is the preferred substrate for Yersinia outer protein T-catalyzed cleavage with a 3fold faster turnover rate over Rac and Cdc42
-
3-([(2E)-2-cyano-3-(4-methoxy-3-[(naphthalen-1-ylcarbonyl)oxy]phenyl)prop-2-enoyl]amino)benzoic acid
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
3-([(2E)-2-cyano-3-(4-methoxy-3-[(naphthalen-1-ylcarbonyl)oxy]phenyl)prop-2-enoyl]amino)benzoic acid
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
3-([(2E)-2-cyano-3-(4-methoxy-3-[(naphthalen-1-ylcarbonyl)oxy]phenyl)prop-2-enoyl]amino)benzoic acid
-
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
3-([(2E)-2-cyano-3-(4-methoxy-3-[(naphthalen-1-ylcarbonyl)oxy]phenyl)prop-2-enoyl]amino)benzoic acid
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
5-(3-chloro-4-[(3-fluorobenzyl)oxy]-5-methoxybenzyl)-1-(4-hydroxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
5-(3-chloro-4-[(3-fluorobenzyl)oxy]-5-methoxybenzyl)-1-(4-hydroxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
5-(3-chloro-4-[(3-fluorobenzyl)oxy]-5-methoxybenzyl)-1-(4-hydroxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
-
5-(3-chloro-4-[(3-fluorobenzyl)oxy]-5-methoxybenzyl)-1-(4-hydroxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
5-chloro-3-(2-oxo-2-(4-[3-(trifluoromethyl)phenyl]piperazin-1-yl)ethyl)-1H-indole-2-carboxylic acid
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
5-chloro-3-(2-oxo-2-(4-[3-(trifluoromethyl)phenyl]piperazin-1-yl)ethyl)-1H-indole-2-carboxylic acid
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
5-chloro-3-(2-oxo-2-(4-[3-(trifluoromethyl)phenyl]piperazin-1-yl)ethyl)-1H-indole-2-carboxylic acid
-
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
5-chloro-3-(2-oxo-2-(4-[3-(trifluoromethyl)phenyl]piperazin-1-yl)ethyl)-1H-indole-2-carboxylic acid
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
Clostridium botulinum exoenzyme C3
-
specific inhibitor
-
Clostridium botulinum exoenzyme C3
-
specific inhibitor
-
ethyl ([2-(2-methoxy-4-((Z)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl)phenoxy)ethyl]sulfanyl)acetate
-
ethyl ([2-(2-methoxy-4-((Z)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl)phenoxy)ethyl]sulfanyl)acetate
-
ethyl ([2-(2-methoxy-4-((Z)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl)phenoxy)ethyl]sulfanyl)acetate
-
-
ethyl ([2-(2-methoxy-4-((Z)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl)phenoxy)ethyl]sulfanyl)acetate
-
GDP
-
inhibition of binding of GTP[S], Ki: ca. 0.001 mM
GDP
the activation state of Rac1 depends on the release of guanosine diphosphate and the binding of guanosine triphosphate. This cycling is regulated by the guanine nucleotide exchange factors, as activators, and by the GTPase activating proteins; the activation state of Rac1 depends on the release of guanosine diphosphate and the binding of guanosine triphosphate. This cycling is regulated by the guanine nucleotide exchange factors, as activators, and by the GTPase activating proteins; the activation state of Rac1 depends on the release of guanosine diphosphate and the binding of guanosine triphosphate. This cycling is regulated by the guanine nucleotide exchange factors, as activators, and by the GTPase activating proteins
GDP
Rab proteins exist in the active GTP-bound and inactive GDP-bound conformations with the GTP/GDP exchange mediated by GTP exchange factors (GEF53) and it is the GTP-bound active form of Rab that promotes membrane trafficking upon interaction with effector proteins
GTP
-
inhibition of GTP[S]-binding at increasing concentrations
GTP
-
competitive inhibition of GTPase activity
guanine nucleotide dissociation inhibitor GDI
-
-
-
guanine nucleotide dissociation inhibitor GDI
-
inhibits the dissociation of GDP from and the binding of GTP to rhoB p20
-
guanine nucleotide dissociation inhibitor GDI
-
down-regulating GTPase activity, inhibition of nucleotide dissociation
-
guanine nucleotide dissociation inhibitor GDI
-
-
-
guanine nucleotide dissociation inhibitor GDI
-
down-regulating GTPase activity, inhibition of nucleotide dissociation
-
guanine nucleotide dissociation inhibitor GDI
-
down-regulating GTPase activity, inhibition of nucleotide dissociation
-
N-(2-acetylphenyl)-4-([2-(4-chloro-2-methylphenoxy)propanoyl]amino)benzamide
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
N-(2-acetylphenyl)-4-([2-(4-chloro-2-methylphenoxy)propanoyl]amino)benzamide
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
N-(2-acetylphenyl)-4-([2-(4-chloro-2-methylphenoxy)propanoyl]amino)benzamide
-
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
N-(2-acetylphenyl)-4-([2-(4-chloro-2-methylphenoxy)propanoyl]amino)benzamide
the compound is both biologically active against bacterial cells and a putative enzymatic inhibitor of Der GTPase homologue
NSC23766
-
not very potent inhibitor of Rac1 and Cdc42
NSC23766
-
a small molecule antagonist of Rac activation
NSC23766
-
Rac-specific inhibitor
Rap1GAP1
-
a GTPase-activating protein that inhibits Rap1 activity
-
Rap1GAP1
-
a GTPase-activating protein that inhibits Rap1 activity
-
additional information
-
exposure of confluent lung endothelial cell monolayers to wild type Pseudomonase aeruginosa strain PAK causes a significant decrease in Rac1 activity within 10 min
-
additional information
structure-based design of enzyme Der inhibitors using the X-ray crystal structure of Thermotoga maritima Der, computer-aided pharmacophore modeling. Analysis of the interactions of the inhibitory compounds with the Der GTP-binding site to understand the mechanism of inhibition. No or poor inhibition by 3-[(4Z)-5-hydroxy-3-methyl-4-([5-(2-methyl-5-nitrophenyl)furan-2-yl]methylidene)-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 3-[(4Z)-4-([5-(3-acetylphenyl)furan-2-yl]methylidene)-5-hydroxy-3-methyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 2-((Z)-[3-(4-carboxyphenyl)-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl)benzoic acid, (4E)-4-(2-[2-(3-methoxyphenoxy)ethoxy]benzylidene)-1-phenylpyrazolidine-3,5-dione, 3,4-bis([(3,4-dimethylphenoxy)acetyl]amino)benzoic acid, 2-(5,5-dimethyl-3-methylidenehexyl)-1-methyl-5-(3-adamantylbutyl)-3-propylbenzene, and 2-(3-([((2-[2-(dimethylamino)ethyl]-1H-indol-3-yl)methyl)sulfanyl]methyl)-5-methyl-1H-indol-2-yl)-N,N-dimethylethanamine
-
additional information
structure-based design of enzyme Der inhibitors using the X-ray crystal structure of Thermotoga maritima Der, computer-aided pharmacophore modeling. Analysis of the interactions of the inhibitory compounds with the Der GTP-binding site to understand the mechanism of inhibition. No or poor inhibition by 3-[(4Z)-5-hydroxy-3-methyl-4-([5-(2-methyl-5-nitrophenyl)furan-2-yl]methylidene)-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 3-[(4Z)-4-([5-(3-acetylphenyl)furan-2-yl]methylidene)-5-hydroxy-3-methyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 2-((Z)-[3-(4-carboxyphenyl)-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl)benzoic acid, (4E)-4-(2-[2-(3-methoxyphenoxy)ethoxy]benzylidene)-1-phenylpyrazolidine-3,5-dione, 3,4-bis([(3,4-dimethylphenoxy)acetyl]amino)benzoic acid, 2-(5,5-dimethyl-3-methylidenehexyl)-1-methyl-5-(3-adamantylbutyl)-3-propylbenzene, and 2-(3-([((2-[2-(dimethylamino)ethyl]-1H-indol-3-yl)methyl)sulfanyl]methyl)-5-methyl-1H-indol-2-yl)-N,N-dimethylethanamine
-
additional information
-
regulation of Cdc42 activity; regulation of Rac1 activity; regulation of RhoA activity
-
additional information
accumulation of acetylated alpha-tubulin by TSA treatment decreases the phosphorylation level of S6K1
-
additional information
three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity; three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity; three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity
-
additional information
three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity; three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity; three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity
-
additional information
three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity; three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity; three categories of selective Rac1 inhibitors affect different steps of the GTP/GDP pathway of enzyme activation: antagonists of Rac1-guanine nucleotide exchange factor interaction, allosteric inhibitors of nucleotide binding to Rac1, and antagonists of Rac1-mediated NADPH oxidase activity
-
additional information
Rab proteins are members of the Ras superfamily of GTPases that switch between GDP-bound (inactive) and GTP-bound (active) forms
-
additional information
-
Rab proteins are members of the Ras superfamily of GTPases that switch between GDP-bound (inactive) and GTP-bound (active) forms
-
additional information
most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation; most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation; most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation
-
additional information
most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation; most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation; most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation
-
additional information
most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation; most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation; most RhoGTPases bind to chaperones, called guanine nucleotide dissociation inhibitors (RhoGDIs), which are cytosolic proteins that lack enzymatic activity. GDIs retain RhoGTPases in the inactive conformation, sequester them from cellular membranes and protect the GTPase from effector binding and proteolytic degradation
-
additional information
-
RhoE downregulates the activity of RhoA by activating p190RhoGAP
-
additional information
RhoA- or ROCK-induced inhibitions are partially relieved upon incubation of the oocytes with the ROCK inhibitor Y27632
-
additional information
-
structure-based design of enzyme Der inhibitors using the X-ray crystal structure of Thermotoga maritima Der, computer-aided pharmacophore modeling. Analysis of the interactions of the inhibitory compounds with the Der GTP-binding site to understand the mechanism of inhibition. No or poor inhibition by 3-[(4Z)-5-hydroxy-3-methyl-4-([5-(2-methyl-5-nitrophenyl)furan-2-yl]methylidene)-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 3-[(4Z)-4-([5-(3-acetylphenyl)furan-2-yl]methylidene)-5-hydroxy-3-methyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 2-((Z)-[3-(4-carboxyphenyl)-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl)benzoic acid, (4E)-4-(2-[2-(3-methoxyphenoxy)ethoxy]benzylidene)-1-phenylpyrazolidine-3,5-dione, 3,4-bis([(3,4-dimethylphenoxy)acetyl]amino)benzoic acid, 2-(5,5-dimethyl-3-methylidenehexyl)-1-methyl-5-(3-adamantylbutyl)-3-propylbenzene, and 2-(3-([((2-[2-(dimethylamino)ethyl]-1H-indol-3-yl)methyl)sulfanyl]methyl)-5-methyl-1H-indol-2-yl)-N,N-dimethylethanamine
-
additional information
structure-based design of enzyme Der inhibitors using the X-ray crystal structure of Thermotoga maritima Der, computer-aided pharmacophore modeling. Analysis of the interactions of the inhibitory compounds with the Der GTP-binding site to understand the mechanism of inhibition. No or poor inhibition by 3-[(4Z)-5-hydroxy-3-methyl-4-([5-(2-methyl-5-nitrophenyl)furan-2-yl]methylidene)-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 3-[(4Z)-4-([5-(3-acetylphenyl)furan-2-yl]methylidene)-5-hydroxy-3-methyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 2-((Z)-[3-(4-carboxyphenyl)-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl)benzoic acid, (4E)-4-(2-[2-(3-methoxyphenoxy)ethoxy]benzylidene)-1-phenylpyrazolidine-3,5-dione, 3,4-bis([(3,4-dimethylphenoxy)acetyl]amino)benzoic acid, 2-(5,5-dimethyl-3-methylidenehexyl)-1-methyl-5-(3-adamantylbutyl)-3-propylbenzene, and 2-(3-([((2-[2-(dimethylamino)ethyl]-1H-indol-3-yl)methyl)sulfanyl]methyl)-5-methyl-1H-indol-2-yl)-N,N-dimethylethanamine
-
additional information
-
structure-based design of enzyme Der inhibitors using the X-ray crystal structure of Thermotoga maritima Der, computer-aided pharmacophore modeling. Analysis of the interactions of the inhibitory compounds with the Der GTP-binding site to understand the mechanism of inhibition. No or poor inhibition by 3-[(4Z)-5-hydroxy-3-methyl-4-([5-(2-methyl-5-nitrophenyl)furan-2-yl]methylidene)-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 3-[(4Z)-4-([5-(3-acetylphenyl)furan-2-yl]methylidene)-5-hydroxy-3-methyl-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid, 2-((Z)-[3-(4-carboxyphenyl)-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl)benzoic acid, (4E)-4-(2-[2-(3-methoxyphenoxy)ethoxy]benzylidene)-1-phenylpyrazolidine-3,5-dione, 3,4-bis([(3,4-dimethylphenoxy)acetyl]amino)benzoic acid, 2-(5,5-dimethyl-3-methylidenehexyl)-1-methyl-5-(3-adamantylbutyl)-3-propylbenzene, and 2-(3-([((2-[2-(dimethylamino)ethyl]-1H-indol-3-yl)methyl)sulfanyl]methyl)-5-methyl-1H-indol-2-yl)-N,N-dimethylethanamine
-